Ottobock leads USD 10.5 million Blue Arbor round while Ottobock stock sits below EUR 49.00

Published on 10/29/2026 at 09:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RESTORE will support U.S. clinical studies and prosthetic control. Ottobock stock costs EUR 48.90 on October 29, 2026, below EUR 49.00.

Ottobock expands prosthetic technology

Ottobock led Blue Arbor Technologies' USD 10.5 million Series A financing on October 28, 2026.
The RESTORE system has completed two successful human implantations, according to the financing release.
Ottobock stock trades at EUR 48.90 at 9:36 a.m. CET at Lang & Schwarz on October 29, 2026, 0.20 percent below the Xetra close of October 28, 2026.

Ottobock, DE000BCK2223, Illustration mit AI erstellt.

Ottobock (ISIN DE000BCK2223) led a USD 10.5 million Series A financing for Blue Arbor Technologies, giving the medical technology group a larger role in the development of neuromuscular prosthetic control. The original Business Wire release dated October 28, 2026 said the round was led by Ottobock and will fund feasibility work, U.S. clinical studies and further development of the RESTORE Neuromuscular Interface System.

A larger prosthetic bet

RESTORE is designed to support independent and simultaneous control of the fingers, wrist and elbow. Blue Arbor is developing an external sensing unit and a fully implantable internal sensing unit, while the release said two human implantations had already been completed.

Oliver Jakobi, Ottobock's chief executive officer, said the investment targets areas that complement the group's core business and offer long-term growth potential. The financing therefore adds a concrete technology initiative to Ottobock's established prosthetics, neuro-orthotics and exoskeleton activities.

What does the investment add?

The project has a defined regulatory pathway rather than a commercial product launch. Blue Arbor plans feasibility studies and an application for a U.S. FDA Investigational Device Exemption, while the RESTORE system has received FDA Breakthrough Device Designation and entered the Total Product Life Cycle Advisory Program pilot, according to Business Wire.

Three recent Ottobock markers

On August 13, 2026, Ottobock reported first-half results through its investor page, which lists fiscal year 2025 core revenue of EUR 0.2 billion and adjusted core EBITDA of EUR 52.5 million. On October 2, 2026, its corporate newsroom said SUITX solutions were available at more than 90 Würth branches in Germany and planned for more than 100 by year-end. On October 28, 2026, Ottobock led Blue Arbor's USD 10.5 million financing, as Ottobock and its investor site provide the operating context.

Dates investors can track

Ottobock's investor calendar lists the third-quarter 2026 quarterly communication for November 12, 2026, followed by a BNP Paribas MidCap CEO Conference on November 16, 2026.

Stock remains below EUR 49.00

The new financing is strategic rather than a near-term earnings update. Its investor relevance rests on whether clinical progress can turn Ottobock's prosthetic expertise into additional products and partnerships.

Ottobock stock was trading at EUR 48.90 at Lang & Schwarz on October 29, 2026 at 9:36 a.m. CET, 0.20 percent below the Xetra close of October 28, 2026 at EUR 49.00. The further course of trading is shown by the continuously updated real-time quote of Ottobock stock.